Preparation and application of Ankang fish polypeptide with repairing effect

文档序号：1500173 发布日期：2020-02-07 浏览：17次中文

阅读说明：本技术 一种具有修复作用的安康鱼肉多肽的制备及应用 (Preparation and application of Ankang fish polypeptide with repairing effect ) 是由杨最素于 2019-10-10 设计创作，主要内容包括：本发明涉及生物技术提取领域,针对现有技术的发明物分子活性不足及药物修复成分针对性较弱的问题,公开了一种具有修复作用的安康鱼肉多肽的制备及应用,包括以下步骤：安康鱼肉预处理；酶解；过滤得澄清液；分离纯化；除杂除菌；多肽分级。提供一种对非酒精性脂肪肝具有修复作用的安康鱼肉多肽的提取工艺及应用效果,可明显降低非酒精性脂肪肝模型(NAFLD)血清中ALT和AST活性；安康鱼肉多肽提取率高、提取纯度高,对NAFLD具有优良的修复作用,生物活性稳定,可保持时间较长；能有针对性的对非酒精性脂肪肝进行修复,修复效果较好并且该提取工艺的可控性好,易于实际大规模工业化量产。(The invention relates to the field of extraction of biotechnology, and discloses preparation and application of an anglerfish polypeptide with a repairing effect aiming at the problems of insufficient molecular activity of an invention and weak pertinence of a medicine repairing component in the prior art, wherein the preparation and application comprise the following steps: pretreating anglerfish flesh; carrying out enzymolysis; filtering to obtain clear liquid; separating and purifying; removing impurities and bacteria; and (4) grading the polypeptide. Provides an extraction process and application effect of an anglerfish polypeptide with repair effect on non-alcoholic fatty liver, can obviously reduce ALT and AST activity in non-alcoholic fatty liver model (NAFLD) serum; the Ankang fish polypeptide has high extraction rate and high extraction purity, has excellent repair effect on NAFLD, has stable biological activity and can be kept for a long time; the non-alcoholic fatty liver can be repaired in a targeted manner, the repairing effect is good, the extraction process is good in controllability, and the actual large-scale industrial mass production is easy to realize.)

1. The preparation method of the Ankang fish polypeptide with the repairing effect is characterized by comprising the following steps:

(1) and (3) pretreating anglerfish meat: thawing and cleaning anglerfish, mincing, and defatting with 94-96% ethanol water bath at 48-52 deg.C at a material-liquid ratio of 1:4-6(m/v) for 2-2.2 h; after degreasing, pouring out the supernatant, cleaning the precipitate with pure water, centrifuging the degreased fish meat for 15-20min at the temperature of 2-6 ℃ and the temperature of 11900 and 12000r/min, collecting the precipitate, and freezing the precipitate at the temperature of-18-20 ℃ for later use;

(2) and enzymolysis: adding fish meat into enzymolysis liquid containing neutral protease for enzymolysis; wherein the concentration of the neutral protease is 0.05-0.25wt%, the mass of the enzymolysis liquid is 2-4 times of the mass of the fish, the enzymolysis temperature is 30-45 ℃, the pH value of the enzymolysis liquid is controlled to be 6.5-8.5, and the enzymolysis time is 5-5.4 h;

(3) filtering to obtain a clear solution: adding modified active carbon with the mass of 1-2wt% of the enzymolysis liquid into the enzymolysis liquid, heating the enzymolysis liquid to 70-80 ℃, and decoloring for 30-50 min; transferring the decolorized enzymatic hydrolysate to a plate-and-frame filter tank for filtering, and taking a clear solution;

(4) and separation and purification: bubbling the clarified liquid by air, collecting the foam liquid, and injecting water while bubbling; the air blowing rate is 3-4L/min, the water injection rate is 0.2-0.3L/min, and the temperature of the clarified liquid is kept at 25-35 ℃; after the collected foam liquid is extinguished, carrying out heavy metal separation on the foam liquid; adding magnetic affinity microspheres with the mass of 1-2% of the foam liquid into the foam liquid after heavy metal separation, uniformly dispersing, standing for affinity adsorption for 50-70min, and then utilizing a magnetic field to aggregate the magnetic affinity microspheres; after separating out the magnetic affinity microspheres, eluting the magnetic affinity microspheres by using Tris-HCl buffer solution with the pH value of 7-7.2, separating out the magnetic affinity microspheres by using a magnetic field again to obtain eluent, and storing the eluent at 75-85 ℃ for later use;

(5) removing impurities and bacteria: filtering the eluate with two-stage 0.22 micrometer membrane to remove impurities and bacteria; wherein the membrane filtration temperature is less than 45 ℃, the primary filtration pressure is less than 0.25MPa, and the secondary filtration pressure is less than 0.4 MPa;

(6) and polypeptide grading: and (3) separating the concentrated solution after membrane filtration by adopting an ultrafiltration membrane or a nanofiltration membrane according to the molecular weight to obtain the anglerfish polypeptide with the target molecular weight.

2. The preparation method of the Ankang fish polypeptide with repair effect according to claim 1, wherein the modified activated carbon is prepared by the following steps:

a. pretreatment: for the fruit shell activated carbon, firstly soaking the activated carbon for 1.8-2.2h at 60-65 ℃ by using 0.5-0.8mol/L of dilute nitric acid, filtering a sample, then slowly adding 0.8-1mol/L of hydrofluoric acid, soaking for 8-10h at 60-70 ℃, washing to be neutral by using deionized water, then adding deionized water, boiling for 1.8-2.2h at 98-100 ℃, then washing for 2-3 times by using pure water, then placing in an oven at 98-102 ℃, drying, taking out and sealing for later use;

b. modification: weighing the pretreated fruit shell activated carbon, respectively soaking the fruit shell activated carbon in 10-15% of sodium bicarbonate, magnetically stirring for 1.8-2.2h, washing the fruit shell activated carbon with deionized water until the pH value reaches 6.8-7, and drying in a constant-temperature drying oven at 98-102 ℃ for 22-24h to obtain the modified fruit shell activated carbon.

3. The preparation method of the health-improving fish polypeptide as claimed in claim 2, wherein the shell is almond shell.

4. The preparation method of the Ankang fish meat polypeptide with the repairing effect according to claim 2, wherein the mass ratio of the shell activated carbon to the sodium bicarbonate in the step b is 1: 3-4.

5. The preparation method of the Ankang fish polypeptide with repair effect according to claim 1, wherein the preparation method of the magnetic affinity microspheres comprises the following steps:

I. generating magnetic microspheres: mixing and dissolving sodium alginate, polyethylene oxide, chitosan, n-heptane, acetic acid and pure water according to the mass ratio of 2-3:1-1.2:2-2.5:0.5-0.8:3-5:100, and stirring uniformly to obtain a mixed solution A; adding ferroferric oxide magnetic particles accounting for 4-6% of the mixed solution A in mass into the mixed solution A and uniformly dispersing to obtain mixed solution B; carrying out ultrasonic dispersion on the mixed solution B, and simultaneously dropwise adding an emulsion of which the mass is 40-60% of that of the mixed solution B into the mixed solution B at a constant speed to obtain a mixed solution C; adding 97-98wt% of glutaraldehyde which accounts for 0.1-0.2% of the mass of the mixed solution C and 2.5-3.5wt% of potassium bromide which accounts for 0.5-0.8 times of the mass of the mixed solution C into the mixed solution C, fully stirring, and standing for 1-1.2h to generate magnetic microspheres;

II. Aggregating the magnetic microspheres: and (3) utilizing a magnetic field to aggregate the magnetic microspheres in the liquid, taking out the magnetic microspheres, and then cleaning and drying the magnetic microspheres.

6. The preparation method of the Ankang fish polypeptide with repair function according to claim 5, wherein the emulsion in the step I is a mixed solution of 30-35% by volume of diacetyl tartaric acid ester of monoglyceride-80 anhydrous ethanol, and the emulsion is added dropwise within 5-10 min.

7. The method for preparing an anglerfish polypeptide with repairing effect as claimed in claim 1, wherein the target molecular weight in step (6) is 1600-4000 Da.

8. Use of an anglerfish polypeptide according to any one of claims 1-7 for repairing non-alcoholic fatty liver disease in the manufacture of a medicament for repairing non-alcoholic fatty liver disease.

9. The use according to claim 8, wherein an anglerfish polypeptide having a repairing effect on non-alcoholic fatty liver disease has an inhibition rate of 85.3% and shows a fatty liver repairing activity.

10. The use of claim 8, wherein the medicament is an oral medicament.

Technical Field

The invention relates to the field of biotechnological extraction, and particularly relates to preparation and application of an anglerfish polypeptide with a repairing effect.

Background

NAFLD (non alcoholic fatty liver disease) is a pathological syndrome which is mainly characterized by hepatocyte steatosis and fat accumulation, and the conventional treatment method mainly adopts conservative treatments such as weight-reducing treatment, lipid-lowering treatment, angiotensin converting enzyme inhibitor and the like, but the conservative treatment method is lack of a special method at present and has poor effect. In recent years, researchers in China have conducted a great deal of research on the protection of liver damage by extracting bioactive substances from marine animals.

The anglerfish, also known as toad fish, crust fish and the like, is offshore bottom layer fish, is distributed in the western part of the North Pacific ocean, has the characteristics of high protein, low fat, rich mineral content and polyunsaturated fatty acid in coastal waters of China, and has good effect of preventing diseases such as liver and the like.

The patent number CN201910189173.5 is patent name 'prescription for eliminating dampness and activating blood circulation for treating non-alcoholic fatty liver disease', the invention belongs to the field of medicine processing, and particularly relates to a prescription for eliminating dampness and activating blood circulation for treating non-alcoholic fatty liver disease, which mainly adopts lotus leaf, tuckahoe, atractylodes macrocephala, semen cassiae, semen coicis, rhizoma alismatis, grifola, gynostemma pentaphylla, rhizoma pinellinae praeparata, polygonum cuspidatum, oriental wormwood, astragalus, liquorice, dried orange peel, radix bupleuri, radix paeoniae rubra, curcuma zedoary, salvia miltiorrhiza and wine rhubarb as main components of the prescription for eliminating dampness and activating blood circulation for treating non-alcoholic fatty liver disease; cassia seed, coix seed and alisma orientale liver-soothing to eliminate dampness and activate blood. The prescription takes dampness elimination and blood circulation promotion as main lines, and is assisted by products for soothing the liver and clearing heat, so as to relax the liver and collaterals and clear away stagnated heat. The traditional Chinese medicine has the effects of calming the liver, tonifying the spleen, promoting diuresis, reducing phlegm, removing stagnation, activating blood, regulating blood fat and promoting liver cell repair, has a good effect of treating the non-alcoholic fatty liver and has no toxic or side effect.

The defects are that the molecular activity of the compound is insufficient, the pertinence of the medicine repairing components is weak, and the non-alcoholic fatty liver can not be accurately repaired in a targeted manner.

Disclosure of Invention

The invention aims to overcome the problems of insufficient molecular activity and weak pertinence of drug repairing components of the invention in the prior art, and provides the preparation and the use of the Ankang fish polypeptide with the repairing effect.

In order to achieve the purpose, the invention adopts the following technical scheme:

a preparation method of an anglerfish polypeptide with a repairing effect on non-alcoholic fatty liver disease comprises the following steps: (1) and (3) pretreating anglerfish meat: thawing and cleaning anglerfish, mincing, and defatting with 94-96% ethanol water bath at 48-52 deg.C at a material-liquid ratio of 1:4-6(m/v) for 2-2.2 h; after degreasing, pouring out the supernatant, cleaning the precipitate with pure water, centrifuging the degreased fish meat for 15-20min at the temperature of 2-6 ℃ and the temperature of 11900 and 12000r/min, collecting the precipitate, and freezing the precipitate at the temperature of-18-20 ℃ for later use;

Preferably, the preparation steps of the modified activated carbon are as follows:

After sodium bicarbonate is modified, the surface appearance and the structure of the activated carbon are obviously changed. The trench is more severely corroded after the alkalinity enhancement and the structure almost disappears. And the hole then is evenly distributed, and the aperture obviously reduces, and the indent deepens, reachs comparatively complete slot structure, and the hole distributes comparatively evenly, and the hole size then further diminishes, and then promotes the specific surface area of active carbon, promotes the pigment clearance ability of shell active carbon promptly.

Preferably, the shell is almond shell.

The wood activated carbon has strong polarity, can absorb polypeptide with large molecular weight while adsorbing the pigment, so the almond shell activated carbon is selected, has small polarity, can avoid absorption of macromolecular chains while completely removing the pigment, and is an excellent pigment scavenger.

Preferably, the mass ratio of the shell activated carbon to the sodium bicarbonate in the step b is 1: 3-4.

Preferably, the preparation steps of the magnetic affinity microsphere are as follows:

Preferably, the emulsion in the step I is a mixed solution of diacetyl tartaric acid monoglyceride-80 anhydrous ethanol with the volume ratio of 30-35%, and the emulsion is completely dripped within 5-10 min.

Preferably, the target molecular weight in step (6) is 1600-4000 Da.

The application of the anglerfish polypeptide having the repairing effect on the non-alcoholic fatty liver disease in preparing the medicine for repairing the non-alcoholic fatty liver disease.

Preferably, the anglerfish polypeptide having the repairing effect on the non-alcoholic fatty liver disease has the inhibition rate of 85.3 percent, and shows the fatty liver repairing activity.

Preferably, the medicament is an oral medicament.

Therefore, the invention has the following beneficial effects:

(1) provides an extraction process and application effect of an anglerfish polypeptide with repair effect on non-alcoholic fatty liver, can obviously reduce ALT and AST activity in non-alcoholic fatty liver model (NAFLD) serum;

(2) the Ankang fish polypeptide has high extraction rate and high extraction purity, has excellent repair effect on NAFLD, has stable biological activity and can be kept for a long time;

(3) the non-alcoholic fatty liver can be repaired in a targeted manner, the repairing effect is good, the extraction process is good in controllability, and the actual large-scale industrial mass production is easy to realize.

Detailed Description

The invention is further described with reference to specific embodiments.

EXAMPLE 1

A preparation method of an anglerfish polypeptide with a repairing effect on non-alcoholic fatty liver disease comprises the following steps:

(1) and (3) pretreating anglerfish meat: unfreezing and cleaning anglerfish, mincing the anglerfish by a meat mincer, and degreasing the anglerfish by 95% ethanol water bath for 2.1h under the conditions that the material-liquid ratio is 1:5(m/v) and the temperature is 50 ℃; removing supernatant after defatting, cleaning precipitate with pure water, centrifuging defatted fish meat at 4 deg.C and 11950r/min for 18min, collecting precipitate, and freezing at-19 deg.C;

(2) and enzymolysis: adding fish meat into enzymolysis liquid containing neutral protease for enzymolysis; wherein the concentration of the neutral protease is 0.15 wt%, the mass of the enzymolysis liquid is 3 times of that of the fish, the enzymolysis temperature is 38 ℃, the pH value of the enzymolysis liquid is controlled to be 7.5, and the enzymolysis time is 5.2 h;

(3) filtering to obtain a clear solution: adding modified active carbon with the mass of 1.5 wt% of the enzymolysis liquid into the enzymolysis liquid, heating the enzymolysis liquid to 75 ℃, and decoloring for 40 min; transferring the decolorized enzymatic hydrolysate to a plate-and-frame filter tank for filtering, and taking a clear solution;

the preparation steps of the modified activated carbon are as follows:

a. pretreatment: for the fruit shell activated carbon, firstly soaking the activated carbon for 2 hours at 63 ℃ by using 0.7mol/L dilute nitric acid, filtering a sample, then slowly adding 0.9mol/L hydrofluoric acid, soaking for 9 hours at 65 ℃, washing to be neutral by using deionized water, then adding deionized water, boiling for 2 hours at 99 ℃, washing for 3 times by using pure water, then placing in an oven at 100 ℃ for drying, taking out and sealing for later use; b. modification: weighing the pretreated shell activated carbon, respectively soaking the shell activated carbon in 13% sodium bicarbonate, magnetically stirring for 2 hours, washing the shell activated carbon with deionized water until the pH value reaches 6.9, and drying in a constant-temperature drying oven at 100 ℃ for 23 hours to obtain the modified shell activated carbon, wherein the shell is an almond shell, and the mass ratio of the shell activated carbon to the sodium bicarbonate in the step b is 1: 3.5.

(4) And separation and purification: transferring the clarified liquid to a foam separation column for air blowing and foaming, collecting the foam liquid, and injecting water into the foam separation column while blowing air; the air blowing rate is 3.5L/min, the water injection rate is 0.25L/min, the ratio of the loading height of the liquid in the foam separation column to the inner diameter of the foam separation column is 9:1, and the temperature of the clarified liquid is kept at 30 ℃; after the collected foam liquid is extinguished, carrying out heavy metal separation on the foam liquid; adding magnetic affinity microspheres with the mass of 1.5% of the foam liquid into the foam liquid after heavy metal separation, uniformly dispersing, standing for affinity adsorption for 60min, and then aggregating the magnetic affinity microspheres by using a magnetic field; after separating the magnetic affinity microspheres, eluting the magnetic affinity microspheres by using Tris-HCl buffer solution with the pH value of 7.1, separating the magnetic affinity microspheres by using a magnetic field again to obtain eluent, and storing the eluent at 80 ℃ for later use;

the preparation steps of the magnetic affinity microsphere are as follows:

I. generating magnetic microspheres: mixing and dissolving sodium alginate, polyethylene oxide, chitosan, n-heptane, acetic acid and pure water in a mass ratio of 2.5:1.1:2.3:0.7:4:100 in a container, and uniformly stirring to obtain a mixed solution A; adding ferroferric oxide magnetic particles accounting for 5% of the mixed solution A in mass into the mixed solution A and uniformly dispersing to obtain mixed solution B; carrying out ultrasonic dispersion on the mixed solution B, and simultaneously dropwise adding an emulsion of which the mass is 50% of that of the mixed solution B into the mixed solution B at a constant speed to obtain a mixed solution C; firstly, 97.5 wt% of glutaraldehyde and 3 wt% of potassium bromide, wherein the mass of the glutaraldehyde is 0.15% of that of the mixed solution C, and the potassium bromide is 0.7 times that of the mixed solution C, are added into the mixed solution C, and the mixed solution C is fully stirred and stands for 1.1h to generate magnetic microspheres; and (3) the emulsion in the step I is a mixed solution of diacetyl tartaric acid monoglyceride and 80 anhydrous ethanol, and the volume ratio of the mixture is 33%, and the emulsion is completely dripped within 8 min.

(5) Removing impurities and bacteria: filtering the eluate with two-stage 0.22 micrometer membrane to remove impurities and bacteria; wherein the membrane filtration temperature is 38 ℃, the primary filtration pressure is 0.2MPa, and the secondary filtration pressure is 0.3 MPa;

The application of the anglerfish polypeptide extracted in the steps in oral drugs is as follows:

1. 24 adult male (ICR) mice were randomly divided into 2 groups after adaptive feeding for 72 hours in a feeding environment, and normal group mice (6) were fed with basal diet and the remaining mice (18) were fed with high fat diet. A mouse NAFLD model is established by adopting high-fat feed induction, and lard oil, sodium cholate and the like are added into a basic feed, wherein the sodium cholate can promote lipid absorption. After 15 days, two mice were taken from the normal group and the high-fat diet model group, sacrificed, livers were taken, and HE staining was performed after embedding for pathological diagnosis, confirming successful modeling. After the model building is successful, randomly dividing 16 mice in the model group into 4 groups, wherein each group comprises 4 mice, and the groups are respectively a model group, a lovastatin positive drug control group, a low dose group and a high dose group; and (3) performing intragastric administration on each group of mice, wherein the dose of each mouse in the positive drug group is 8mg/kg, the doses of the low and high anglerfish polypeptides are 200mg/kg and 400mg/kg respectively, purified water with the same amount is administered to both the normal group and the model group, and the lovastatin solution is prepared: 4.5mg, 6mL of purified water, and mixing well to prepare a suspension. The appearance, behavioral activity, etc. of the animals were observed every day, and the body weights thereof were measured and recorded every two days. Administering for 30 days, feeding stomach in the last day, fasting without water supply for 24 hr, taking blood from eyeball, centrifuging at 4 deg.C for 10min at 4000r/min, and collecting serum for biochemical determination; and observing the weight, behavior, mental state, diet, drinking water and other conditions of the mice. After 30 days of gavage, the normal group mice grew well and were in a normal mental state. The normal group mice had good mobility, normal growth and good mental status. The mice in the model group are listened to, easy to drowse, reduced in activity and slow in response. The low-dose group of the anglerfish polypeptide has poorer mental state and slightly blunted reaction, but the high-dose group has increased activity and the mental state is also improved. Compared with the mice in the model group, the mice in the positive drug group have increased activity and response to the external environment. The body weight changes of the mice are shown in the table 1, and compared with a normal group, the body weight of the high-fat feed model group is remarkably increased by 93.61% (P < 0.05); the increase of the body weight of the positive drug group is not much different from that of the normal group, and the increase is 66.22 percent; the weight gain of the anglerfish peptide dose group is reduced compared with that of the model group, and the anglerfish peptide dose group presents dose dependence, wherein the weight gain of the low dose group is 68.2 percent, the weight gain of the high dose group is 68.48 percent (P < 0.05), and the weight gain of the high dose group is not greatly different from that of the positive drug group;

table 1 weight of each group of mice (n ═ 4)

2. Taking blood from the fundus of a mouse, carrying out cervical dislocation, dissecting, taking a liver after observing the shape of the viscera, washing surface floating blood with precooled physiological saline at 4 ℃, wiping the surface floating blood with filter paper, weighing, and observing the shape of the liver of the mouse. The visceral changes of the mice in each group were visually observed. The liver of the normal group of mice is dark red, and the internal organs have no foreign matters; the abdominal fat of the model group mice is accumulated, the liver is hypertrophied and the color is lighter; compared with a model group, the positive drug group and each dosage group of the Ankang fish polypeptide have the advantages that the abdominal fat accumulation is reduced, the liver color is darker, and the difference between the liver colors of the positive drug group and the normal group is small compared with that of the high dosage group; calculating each index of mouse liver: liver index (%) ═ mouse liver weight (g)/mouse body weight (g) × 100%. Liver indices of mice in each group are shown in Table 2, and liver indices of model groups are significantly increased compared with those of normal groups (P < 0.05). The liver indices decreased in each drug group compared to the model group, with the positive drug group decreasing most and having significant differences (P < 0.05); the liver index decrease amplitude of the high-dose group is larger than that of the low-dose group;

table 2 liver weight index (' x ± s, n ═ 4) for each group of mice

Note: a is compared with the normal group, and P is less than 0.05; b is compared with the model group, and P is less than 0.05;

3. taking blood from eyeball, centrifuging at 4 deg.C for 10min at 4000r/min, collecting serum, and measuring HLD, TG, DLD, AST, and ALT indexes. The activities of ALT and AST in the serum of each group of mice are shown in the table 3, compared with the normal group, the activities of ALT and AST in the model group are obviously improved (P < 0.05), respectively reach 35.86U/L and 55.01U/L which are 2.64 times and 1.93 times of the normal group; the ALT and AST activities of the positive drug group are reduced, and the significant difference (P < 0.05) is presented compared with the model group; the ALT and AST activities of various dose groups of the anglerfish polypeptide are remarkably reduced (P < 0.05) compared with those of a model group, wherein the high dose group has better effect, and the reduction of the ALT and AST activities respectively reach 37.03% and 22.76%, which are not much different from those of a positive drug group. The health-care fish polypeptide can reduce the activity of ALT and AST in serum of a NAFLD mouse, and shows obvious dose correlation along with the increase of the concentration of the health-care fish polypeptide; the contents of HLD, DLD and TG in the sera of the mice in each group are shown in the table 3, and compared with the normal group, the contents of DLD and TG in the model group are obviously increased to 10.23mmol/L and 14.35mmol/L respectively which are 4.16 times and 3.03 times of the contents in the normal group; the content of DLD and TG in the positive drug group is reduced, and the significant difference (P < 0.05) is presented compared with the model group; the content of DLD and TG in each dose group of Ankang fish polypeptide is remarkably reduced compared with that in a model group (P < 0.05), wherein the effect of a high dose group is better, the reduction range of the content of DLD and TG respectively reaches 46.69% and 50.66%, and the difference with a positive drug group is small. The Ankang fish polypeptide can reduce the content of serum DLD and TG of a NAFLD mouse and has obvious dose correlation with the increase of the concentration of the Ankang fish polypeptide. Compared with the normal group, the HLD content of the model group is obviously reduced and is 0.85mmol/L which is 0.31 times that of the normal group: the positive drug group has increased HLD content and shows significant difference compared with the model group (P < 0.05); the HLD content of each dose group of the anglerfish polypeptide is remarkably increased (P < 0.05) compared with that of a model group, wherein the effect of a high dose group is better, the increasing amplitude of the HLD content reaches 109.41%, and the difference with a positive drug group is small. The Ankang fish polypeptide can increase the serum HLD content of a NAFLD mouse, and has obvious dose correlation with the increase of the concentration of the Ankang fish polypeptide.

TABLE 3 serum ALT, AST, HDL, DLD, TG activity (` x. + -. s, n ═ 4) of each group of mice

Group of	ALT/(U/L)	AST/(U/L)	HLD/(mmol/L)	DLD/(mmol/L)	TG/(mmol/L)
						Normal group	12.60±2.24^b	27.48±2.42^b	2.65±0.28^b	2.35±1.76^b	4.54±1.0l^b
Model set	34.86±1.43^a	54.01±1.96^a	0.75±0.24^a	10.43±1.13^a	14.45±2.84^a
						Positive drug group	14.24±2.26^b	35.73±0.12^b	2.02±0.35^b	3.66±0.84^b	5.74±0.18^b
Low dose group	29.51±3.31^a	48.54±0.31^a	l.39±0.18^a	8.79±1.5^r	10.17±1.56^a
						High dose group	21.58±0.1^rb	41.49±1.45^ab	1.68±0.15^ab	5.56±0.14^b	7.13±0.73^b

Note: a is less than 0.05 in comparison with the normal group; b is less than 0.05 in comparison with the model group;

4. accurately weighing mouse liver tissues, and weighing the following components in parts by weight (g): adding 0.9% physiological saline 9 times the volume of the mixture at a ratio of 1:9 (ml), making into 10% homogenate, centrifuging at 4000r/min for 10min, and collecting the supernatant for SOD activity determination. The SOD activity of the liver tissue homogenate of each group of mice is shown in Table 4, and compared with the normal group, the SOD activity of the model group is obviously reduced; the SOD activities of the positive drug group and the high dose group are respectively 1.42 times and 1.34 times of those of the model group, and the significant difference (P < 0.05) is shown;

table 4 liver tissue homogenate SOD activity of each group of mice (' x ± s, n ═ 4)

Group of	SOD CU/mg prot)
		Normal group	75.31±7.81^b
Model set	51.26±6.24^a
		Positive drug group	71.18±7.03^b
Low dose	51.26±2.26^a
		High dose	67.72±6.45^b

Note: a is less than 0.05 in comparison with the normal group; b is less than 0.05 in comparison with the model group;

the conclusion is that excessive FFA is oxidized at β in mitochondria to generate a large amount of active oxygen (ROS) during NAFLD, antioxidant substances in vivo are exhausted, oxidation-antioxidant imbalance causes oxidation stress and lipid peroxidation, mitochondria can be further damaged, on one hand, the mitochondria can be further generated to form malignant cycle, on the other hand, cell apoptosis is further started after mitochondrial membrane permeability is changed, so that the change of liver cell functions can be reflected by detecting indexes which can reflect the change of oxidation and antioxidant substances in mitochondria, such as contents of alanine Aminotransferase (ALT), glutamic-oxalacetic transaminase (AST), superoxide dismutase (SOD) and the like.

11页详细技术资料下载

Preparation and application of Ankang fish polypeptide with repairing effect

相关技术

网友询问留言